Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002308 · ClinicalTrials.gov registry record · NA
A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs
A NA study of HIV Infections, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- NA
- Development phase
- 1
- Study location
NCT00002308 is a NA study of HIV Infections that has completed, run by Bristol-Myers Squibb. The trial reports 1 study location across 1 state.
The verdict
NCT00002308, a NA study of HIV Infections, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- NA
- Development phase
- 1
- Study location
Study Summary
To make stavudine (d4T) available to patients with advanced HIV disease for whom no alternative antiretroviral is satisfactory. To study the safety and efficacy of two dose levels in a twice-daily regimen.
Conditions Studied
Interventions
- DRUG Stavudine
Study Locations (1)
New Jersey
- Bristol - Myers Squibb Co - Princeton
Trial Details
| Field | Value |
|---|---|
| Est. Completion | 1991-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002308
The ClinicalTrials.gov registry entry for NCT00002308 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Stavudine is the first listed.
NCT00002308 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00002308 about?
NCT00002308 is a clinical study titled "A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs". To make stavudine (d4T) available to patients with advanced HIV disease for whom no alternative antiretroviral is satisfactory. To study the safety and efficacy of two dose levels in a twice-daily regimen.
What is the current status of trial NCT00002308?
This trial is currently completed. It is a NA study. Estimated completion is 1991-11.
What conditions does trial NCT00002308 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002308?
The interventions under investigation include: Stavudine (DRUG).
Who is sponsoring clinical trial NCT00002308?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002308 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.